BCDA — BioCardia, Inc.

BioCardia (BCDA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Expenses: Increased by approximately 3% year-over-year to $8.3 million in 2025, up from $8.1 million in 2024.
• R&D Expenses: Rose 13% to $5 million, primarily due to trial closeout activities and regulatory efforts in Japan.
• SG&A Expenses: Decreased by 10% to $3.3 million, attributed to lower professional fees and reduced share-based compensation.
• Net Loss: Increased slightly to $8.2 million from $7.9 million in 2024.
• Net Cash Used in Operations: Approximately $7.5 million, down from $7.9 million in 2024.
• Cash Position: Ended the year with $2.5 million in cash and cash equivalents, comparable to $2.4 million in 2024.

2. Strategic Updates and Business Highlights

• Therapeutic Platforms: Focus on three primary platforms: CardiAMP (autologous cell therapy), CardiALLO (allogeneic cell therapy), and Helix delivery system.
• CardiAMP Therapy: Data from three clinical trials show promising results in treating ischemic heart failure, particularly in patients with elevated biomarkers of heart stress.
• Regulatory Engagement: Preparing for discussions with the FDA and Japan's PMDA regarding potential approval pathways for CardiAMP.
• New Trial Initiation: Launched the CardiAMP HF II confirmatory clinical study, focusing on patients who are the greatest responders from previous trials.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Anticipate four key developments in the next quarter:
  1. FDA submission for CardiAMP HF approval pathway.
  2. Clinical consultation with Japan PMDA regarding CardiAMP.
  3. FDA feedback meeting on the Helix delivery system.
  4. Presentation of CardiAMP data at EuroPCR in May.
• R&D Expense Outlook: Expected to increase modestly in 2026 as the company advances its therapeutic candidates.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: Slow enrollment in the CardiAMP HF II trial due to resource allocation towards regulatory submissions.
• Competitive Landscape: Other companies are pursuing similar therapies, which may create competitive pressures in the market.
• Financial Position: While cash burn is managed, the company’s cash reserves are limited, which could impact future operational flexibility.

5. Notable Q&A Insights

• Echocardiography Data: The p-values for diastolic and systolic volumes were close to statistical significance, with a focus on subgroup analysis for patients with elevated NT-proBNP.
• Regulatory Timeline: The FDA submission for CardiAMP is expected to be filed imminently, with a potential 45-day turnaround for feedback.
• Post-Marketing Studies: Anticipated to be extensive, focusing on long-term survival data and biomarker monitoring.
• Competitive Positioning: CardiAMP is seen as a leading therapy due to its straightforward application and compelling efficacy data compared to other emerging therapies.

This summary encapsulates the key points from BioCardia's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and areas of concern.